| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 8.680 | 16.079 | 16.704 | 16.540 | 12.931 | 46.376 | 54.003 | 53.234 | 47.887 |
| Total Income - EUR | - | 8.680 | 16.079 | 16.704 | 16.540 | 12.931 | 46.443 | 54.003 | 53.234 | 47.887 |
| Total Expenses - EUR | - | 5.101 | 2.711 | 4.839 | 6.611 | 8.387 | 11.903 | 13.775 | 16.631 | 15.547 |
| Gross Profit/Loss - EUR | - | 3.578 | 13.368 | 11.865 | 9.929 | 4.544 | 34.540 | 40.228 | 36.603 | 32.341 |
| Net Profit/Loss - EUR | - | 3.318 | 12.885 | 11.364 | 9.433 | 4.171 | 33.175 | 38.899 | 36.081 | 30.904 |
| Employees | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Endocrinomed F.a. S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 0 | 895 | 18.256 | 13.567 | 9.131 | 4.278 | 1.839 | 649 |
| Current Assets | - | 3.476 | 13.024 | 10.670 | 266 | 3.762 | 24.365 | 34.905 | 35.100 | 31.899 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | 0 | 0 | 0 | 0 | 2.655 | 22.409 | 33.840 | 31.570 | 30.730 |
| Cash | - | 3.476 | 13.024 | 10.670 | 266 | 1.107 | 1.956 | 1.065 | 3.529 | 1.169 |
| Shareholders Funds | - | 3.362 | 12.938 | 11.416 | 18.520 | 16.965 | 33.223 | 38.948 | 36.130 | 30.952 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 114 | 86 | 149 | 2 | 364 | 273 | 236 | 809 | 1.596 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Endocrinomed F.a. S.r.l.